iously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following the initiation of zorbtive ® therapy [see warnings and precautions (5.9) ] . however, formal drug interaction studies have not been conducted. 7.2 cytochrome p450-metabolized drugs limited published data indicate that somatropin treatment increases cytochrome p450 (cyp450)-mediated antipyrine clearance in humans, which involves multiple isozymes including cyp1a2, cyp2b6, cyp2c8, cyp2c9, cyp2c18, and cyp3a4. these data suggest that somatropin administration may alter the clearance of compounds metabolized by cyp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine). when somatropin is administered in combination with these drugs, monitor clinical response to the cyp-metabolized drug, as dosage adjustments may be required. however, formal drug interaction studies have not been conducted. 7.3 oral estrogen because oral estrogens may reduce the serum igf-1 response to somatropin treatment, females receiving oral estrogen replacement may have reduced efficacy from zorbtive ® . however, formal drug interaction studies have not been conducted. monitor patients taking oral estrogens for lack of efficacy of zorbtive ® . 7.4 insulin and/or other oral/injectable hypoglycemic agents patients with diabetes mellitus who receive concomitant antidiabetic treatment with zorbtive ® may require adjustment of their doses of insulin and/or other hypoglycemic agents [see warnings and precautions (5.3) ] . however, formal drug interaction studies have not been conducted.

ymptoms do not resolve. ( 2.1 , 5.7 ) pancreatitis: consider pancreatitis in any patient who develops abdominal pain. ( 5.8 ) hypoadrenalism : monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism. ( 5.9 , 7.1 ) hypothyroidism: evaluate thyroid function in patients with suspected and/or diagnosed hypopituitarism before starting zorbtive ® and again following 4 weeks of treatment; correct thyroid function, if needed. ( 5.10 ) intracranial hypertension: exclude preexisting papilledema. ( 5.11 ) risk of serious adverse reactions in infants due to benzyl alcohol preservative: zorbtive ® is not approved for use in pediatric patients ( 5.12 , 8.4 ) 5.1 neoplasms zorbtive ® is contraindicated in patients with active malignancy. any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. discontinue somatropin if there is evidence of recurrent activity [see contraindications (4) ] . in childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropins after their first neoplasm. intracranial tumors, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms. in adult cancer survivors, the risk of occurrence is unknown. given the limited data available, patients under growth hormone therapy should be carefully monitored for progression or recurrence of the tumor. the safety and effectiveness of zorbtive ® in the treatment for short bowel syndrome in pediatric patients have not been established and zorbtive ® is not approved for use in pediatric patients. monitor patients on somatropin therapy carefully for potential malignant changes of preexisting nevi. 5.2 acute critical illness increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of somatropin [see contraindications (4) ]. two placebo-controlled clinical trials in non-growth hormone deficient adult patients (n=522) with these conditions in intensive care units revealed a significant increase in mortality (42% vs. 19%) among somatropin-treated patients (doses 5.3 to 8 mg per day) compared to those receiving placebo. discontinue zorbtive ® if the patient has acute critical illness. 5.3 impaired glucose tolerance/diabetes mellitus the use of somatropins have been associated with cases of new onset impaired glucose intolerance, new onset type 2 diabetes mellitus and exacerbation of preexisting diabetes mellitus. some patients developed diabetic ketoacidosis and diabetic coma. in some patients, these conditions improved when the drug was discontinued, while in others the glucose intolerance persisted. some patients necessitated initiation or adjustment of antidiabetic treatment (e.g., insulin and/or other oral/injectable hypoglycemic agents) while on somatropin. monitor blood glucose in patients with other risk factors for glucose intolerance during zorbtive ® therapy and adjust antidiabetic treatment, as needed . 5.4 hypersensitivity reactions serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products. inform patients and caregivers that such reactions are possible and to seek prompt medical attention if a hypersensitivity reaction occurs. [see contraindications (4) ] . 5.5 lipoatrophy when somatropins are administered subcutaneously at the same site over a long period of time, tissue atrophy may result. avoid tissue atrophy by rotating the injection site [see dosage and administration (2.3) ] . 5.6 fluid retention and arthralgia increased fluid retention resulting in tissue turgor (swelling, particularly in the hands and feet) and arthralgia resulting in musculoskeletal discomfort (pain, swelling and/or stiffness) may occur during treatment with zorbtive ® , but may resolve spontaneously or with analgesic therapy or after reducing the dosage [see dosage and administration (2.1) ]. 5.7 carpal tunnel syndrome carpal tunnel syndrome may occur during treatment with somatropin. if the symptoms of carpal tunnel syndrome do not resolve by decreasing the dosage of zorbtive ® , discontinue treatment [see dosage and administration (2.1) ] . 5.8 pancreatitis cases of pancreatitis have been reported in pediatric patients and adults receiving somatropin treatment, with some evidence supporting a greater risk in pediatric patients compared with adults. published literature indicates that females who have turner syndrome may be at greater risk than other somatropin-treated pediatric patients. pancreatitis should be considered in any somatropin-treated patient, especially a pediatric patient who develops abdominal pain. the safety and effectiveness of zorbtive ® in the treatment for short bowel syndrome in pediatric patients have not been established and zorbtive ® is not approved for use in pediatric patients. 5.9 hypoadrenalism patients receiving somatropin therapy who have or are at risk for pituitary homone deficiency(s) may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. in addition, patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of zorbtive ® therapy [see drug interactions (7.1) ]. 5.10 hypothyroidism growth hormone can affect the metabolism of thyroid hormones by increasing the extrathyroidal conversion of t4 to t3 and this lowering effect on t4 may unmask incipient central hypothyroidism in hypopituitary patients. evaluate thyroid function in patients with suspected and/or diagnosed hypopituitarism before starting zorbtive ® therapy and again following 4 weeks of treatment. if hypothyroidism is diagnosed following a course of zorbtive ® therapy, it should be corrected. 5.11 intracranial hypertension no cases of intracranial hypertension (ih) have been observed among patients with short bowel syndrome treated with zorbtive ® . the syndrome of intracranial hypertension (ih), with papilledema, visual changes, headache, and nausea and/or vomiting has been reported in a small number of pediatric patients with growth failure treated with somatropins. symptoms usually occurred within the first 8 weeks after the initiation of somatropin therapy. ih-associated signs and symptoms usually resolved after cessation of therapy or a reduction of the somatropin dosage. the safety and effectiveness of zorbtive ® in the treatment for short bowel syndrome in pediatric patients have not been established and zorbtive ® is not approved for use in pediatric patients. funduscopic evaluation of patients is recommended at the initiation of zorbtive ® therapy and if patients present with symptoms of ih. if papilledema is observed by funduscopy during zorbtive ® treatment, discontinue treatment. 5.12 risk of serious adverse reactions in infants due to benzyl alcohol preservative zorbtive ® is not approved for use in neonates or infants. serious and fatal adverse reactions including "gasping syndrome" can occur in neonates and low birth weight infants treated with benzyl alcohol-preserved drugs, including zorbtive ® when reconstituted with bacteriostatic water for injection, usp. the "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. the minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known (when reconstituted with bacteriostatic water for injection, usp, zorbtive ® contains 9 mg of benzyl alcohol per ml) [see use in specific populations (8.4) ].

bcutaneously once daily. permanently discontinue zorbtive ® , if severe toxicity recurs or does not disappear within 5 days. 2.2 preparation instructions zorbtive ® is provided in a package that contains all items required to reconstitute and inject the drug [see how supplied/storage and handling (16) ]. prepare zorbtive ® using the following steps. 1. determine the volume needed for the prescribed dosage based on the patient's weight and recommended dosage. patient weight should be rounded to the nearest kilogram when determining dose. table 1 below provides the volume of diluent to be added for the reconstitution and concentration of the reconstituted solution for zorbtive ® vial 8.8 mg. table 1: reconstitution of injection adult patient weight (kg) volume of diluent to be added for the reconstitution (ml) concentration of reconstituted solution (mg/ml) more than 44 kg 1 ml 8.8 mg/ml less than or equal to 44 kg 2 ml 4.4 mg/ml 2. use appropriate aseptic technique when preparing and administering zorbtive ® . 3. reconstitute the vial(s) of zorbtive ® with either 1 ml or 2 ml of bacteriostatic water for injection, usp (containing benzyl alcohol) using a 3 ml syringe. inject the appropriate amount of diluent into the vial of zorbtive ® aiming the liquid against the glass vial wall. for patients unable to receive benzyl alcohol, zorbtive ® may be reconstituted with sterile water for injection, usp [see warnings and precautions (5.12) ]. 4. gently swirl the vial in circles until the contents are dissolved completely. do not shake. 5. visually inspect the reconstituted solution. the final reconstituted solution should be clear and colorless. discard the vial if the solution is cloudy or contains particulate matter. 2.3 administration instructions withdraw the required volume of the reconstituted solution using a 1 ml syringe with a 29-gauge needle. inject the full contents of the syringe subcutaneously at a 90° angle into the top side of the thigh, the areas around the belly button, the back of the upper arms, and the buttocks or hips. rotate injection sites and do not give injections into areas where the skin is tender, bruised, red, or hard. 2.4 storage of diluted solution once reconstituted with bacteriostatic water for injection, usp (containing benzyl alcohol), zorbtive ® should be stored under refrigeration (2 to 8°c/36 to 46°f) and for no more than 14 days. do not freeze. if zorbtive ® is reconstituted with sterile water for injection, usp, the reconstituted solution should be used immediately and any unused solution should be discarded .

flatulence, and abdominal pain. ( 6.1 ) to report suspected adverse reactions, contact emd serono at 1-800-283-8088 ext. 5563 or fda at 1-800-fda-1088 or www.fda.gov/medwatch . 6.1 clinical trials experience because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot always be directly compared to the rates in the clinical trials of another drug, and may not reflect the adverse reaction rates observed in practice. in a double-blind, randomized, placebo-controlled clinical trial, 32 patients were exposed to zorbtive ® for 4 weeks. of the 41 patients enrolled in the trial, 16 patients received zorbtive ® (0.1 mg/kg per day) plus supportive oral diet, 16 patients received subcutaneous zorbtive ® (0.1 mg/kg per day) plus supportive oral diet plus oral glutamine (30 grams per day), and 9 patients received placebo with specialized oral diet and oral glutamine (30 grams per day). the most common adverse reactions occurring in greater than 20% of patients treated with zorbtive ® alone and at a higher frequency than in the control group include peripheral edema, facial edema, arthralgia, injection site pain, flatulence, and abdominal pain. table 2 summarizes adverse reactions that occurred in at least 10% of patients receiving zorbtive ® , alone or in combination with glutamine and at a higher incidence than in the control group. table 2: adverse reactions occurring at in ≥10% of zorbtive ® -treated patients and at a higher incidence than control in a randomized, placebo controlled trial of zorbtive ® in adult patients with short bowel syndrome: 4 week treatment period treatment group adverse reaction zorbtive ® alone zorbtive ® + glutamine control (placebo + glutamine) n=16 n (%) n=16 n (%) n=9 n (%) peripheral edema 11 (69) 13 (81) 1 (11) facial edema 8 (50) 7 (44) 0 (0) arthralgia 7 (44) 5 (31) 0 (0) injection site pain 5 (31) 0 (0) 0 (0) flatulence 4 (25) 4 (25) 2 (22) abdominal pain 4 (25) 2 (13) 1 (11) injection site reaction 3 (19) 4 (25) 1 (11) vomiting 3 (19) 3 (19) 1 (11) pain 3 (19) 1 (6) 1 (11) nausea 2 (13) 5 (31) 0 (0) after 4 weeks of treatment with zorbtive ® patients were discharged for follow-up on a supportive oral diet supplemented either with glutamine or glutamine placebo, and subjects were re-evaluated as outpatients 12 weeks later. no new adverse drug reactions were observed in the follow up period. 6.2 postmarketing experience the following adverse reactions have been identified during post-approval use of zorbtive ® or other somatropin products. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. zorbtive ® : headache gynecomastia other somatropin products: new onset impaired glucose tolerance, new onset type 2 diabetes mellitus, exacerbation of preexisting diabetes mellitus, diabetic ketoacidosis, diabetic coma [see warnings and precautions (5.3) ] serious systemic hypersensitivity reactions, including anaphylaxis and angioedema [see warnings and precautions (5.4) ] . pancreatitis [see warnings and precautions 5.8) ] leukemia

iously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following the initiation of zorbtive ® therapy [see warnings and precautions (5.9) ] . however, formal drug interaction studies have not been conducted. 7.2 cytochrome p450-metabolized drugs limited published data indicate that somatropin treatment increases cytochrome p450 (cyp450)-mediated antipyrine clearance in humans, which involves multiple isozymes including cyp1a2, cyp2b6, cyp2c8, cyp2c9, cyp2c18, and cyp3a4. these data suggest that somatropin administration may alter the clearance of compounds metabolized by cyp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine). when somatropin is administered in combination with these drugs, monitor clinical response to the cyp-metabolized drug, as dosage adjustments may be required. however, formal drug interaction studies have not been conducted. 7.3 oral estrogen because oral estrogens may reduce the serum igf-1 response to somatropin treatment, females receiving oral estrogen replacement may have reduced efficacy from zorbtive ® . however, formal drug interaction studies have not been conducted. monitor patients taking oral estrogens for lack of efficacy of zorbtive ® . 7.4 insulin and/or other oral/injectable hypoglycemic agents patients with diabetes mellitus who receive concomitant antidiabetic treatment with zorbtive ® may require adjustment of their doses of insulin and/or other hypoglycemic agents [see warnings and precautions (5.3) ] . however, formal drug interaction studies have not been conducted.

of 0.1 mg/kg/day, based on body surface area, respectively, have revealed no evidence of harm to the fetus due to somatropin. in a pre- and post-natal development study in rats, subcutaneous doses of approximately up to 5 times the recommended human dosage of 0.1 mg/kg/day (based on body surface area) had no adverse effect on pre- and post-natal development. 8.2 lactation risk summary there are no data on the presence of somatropin in human milk. limited published literature reports no adverse effects on breastfed infants with maternal administration of somatropin. no decrease in milk production or change in milk content during treatment with somatropin has been reported. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zorbtive ® and any potential adverse effects on the breastfed infant from zorbtive ® or from the underlying maternal condition. 8.4 pediatric use the safety and effectiveness of zorbtive ® in the treatment for short bowel syndrome in pediatric patients have not been established. zorbtive ® is contraindicated in patients with active malignancy. in pediatric cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropins after their first neoplasm. intracranial tumors, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms [see warnings and precautions (5.1) ] . cases of pancreatitis have been reported in patients receiving somatropin treatment, with some evidence supporting a greater risk in pediatric patients compared with adults, particularly females with turner syndrome [see warnings and precautions (5.8) ] . the syndrome of intracranial hypertension (ih), with papilledema, visual changes, headache, and nausea and/or vomiting has been reported in a small number of pediatric patients with growth failure treated with somatropins [see warnings and precautions (5.11) ] . zorbtive ® is not approved for use in neonates or infants. serious adverse reactions including fatal reactions and the "gasping syndrome" occurred in premature neonates and low birth weight infants in the neonatal intensive care unit who received benzyl alcohol as a preservative. in these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/l). additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. the minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known (when reconstituted with bacteriostatic water for injection, usp, zorbtive ® contains 9 mg of benzyl alcohol per ml) [see warnings and precautions (5.12) ] . zorbtive ® is a recombinant human growth hormone and therefore may increase growth and cause growth-related problems (e.g. slipped capital femoral epiphysis) in the patients receiving it, particularly pediatric patients whose epiphyses are not yet closed. 8.5 geriatric use clinical studies with zorbtive ® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. elderly patients may be more sensitive to growth hormone action, and may be more prone to develop adverse reactions. thus, dose selection for an elderly patient should be cautious, usually starting at a lower dose.

dy surface area, respectively, have revealed no evidence of harm to the fetus due to somatropin. in a pre- and post-natal development study in rats, subcutaneous doses of approximately up to 5 times the recommended human dosage of 0.1 mg/kg/day (based on body surface area) had no adverse effect on pre- and post-natal development.

ediatric patients with growth failure treated with somatropins [see warnings and precautions (5.11) ] . zorbtive ® is not approved for use in neonates or infants. serious adverse reactions including fatal reactions and the "gasping syndrome" occurred in premature neonates and low birth weight infants in the neonatal intensive care unit who received benzyl alcohol as a preservative. in these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/l). additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. the minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known (when reconstituted with bacteriostatic water for injection, usp, zorbtive ® contains 9 mg of benzyl alcohol per ml) [see warnings and precautions (5.12) ] . zorbtive ® is a recombinant human growth hormone and therefore may increase growth and cause growth-related problems (e.g. slipped capital femoral epiphysis) in the patients receiving it, particularly pediatric patients whose epiphyses are not yet closed.

s daily dosing as indicated. distribution the steady-state volume of distribution (mean ± sd) following intravenous administration of zorbtive ® in healthy subjects was 12 ± 1 l. elimination somatropin clearance involves both linear and nonlinear, i.e., concentration-dependent, components. the t½ (mean ± sd) in nine patients with hiv-associated wasting with an average weight of 57 ± 7 kg, given a 6 mg dose of somatropin subcutaneously was 4 ± 2 hrs. metabolism although the liver is expected to play a role in the metabolism of somatropin, somatropin is primarily cleaved in the kidney. somatropin undergoes glomerular filtration and, after cleavage within the renal cells, the peptides and amino acids are returned to the systemic circulation. excretion the renal clearance of somatropin after subcutaneous administration in nine patients with hiv-associated wasting was 0.0015 ± 0.0037 l/h. specific populations age: pediatric population available evidence suggests that clearance of somatropin is similar in adults and pediatric patients, but no pharmacokinetic studies have been conducted in pediatric patients with short bowel syndrome. sex literature indicates that a sex-related difference in the mean clearance of somatropins exists (clearance of somatropin is greater in males compared to females). however, no sex-based analysis is available in healthy subjects or patients with short bowel syndrome. renal impairment subjects with chronic renal failure tend to have decreased somatropin clearance compared to those with normal renal function; but the clinical significance in patients with short bowel syndrome treated with zorbtive ® is unknown. hepatic impairment a reduction in somatropin clearance has been noted in patients with severe liver impairment, but the clinical significance in patients with short bowel syndrome treated with zorbtive ® is unknown.

e liver is expected to play a role in the metabolism of somatropin, somatropin is primarily cleaved in the kidney. somatropin undergoes glomerular filtration and, after cleavage within the renal cells, the peptides and amino acids are returned to the systemic circulation. excretion the renal clearance of somatropin after subcutaneous administration in nine patients with hiv-associated wasting was 0.0015 ± 0.0037 l/h. specific populations age: pediatric population available evidence suggests that clearance of somatropin is similar in adults and pediatric patients, but no pharmacokinetic studies have been conducted in pediatric patients with short bowel syndrome. sex literature indicates that a sex-related difference in the mean clearance of somatropins exists (clearance of somatropin is greater in males compared to females). however, no sex-based analysis is available in healthy subjects or patients with short bowel syndrome. renal impairment subjects with chronic renal failure tend to have decreased somatropin clearance compared to those with normal renal function; but the clinical significance in patients with short bowel syndrome treated with zorbtive ® is unknown. hepatic impairment a reduction in somatropin clearance has been noted in patients with severe liver impairment, but the clinical significance in patients with short bowel syndrome treated with zorbtive ® is unknown.

ebo, and patients were re-evaluated as outpatients 12 weeks later. the primary endpoint of the study was the change in weekly total intravenous parenteral nutrition (ipn) volume defined as the sum of the volumes of ipn, supplemental lipid emulsion (sle), and intravenous hydration fluid. the secondary endpoints were the change in weekly ipn caloric content and the change in the frequency of ipn administration per week. the mean baseline ipn volume, mean ipn caloric content, and mean frequency of ipn administration are provided in table 3. mean reductions in ipn volume, ipn caloric content and the frequency of ipn administration in each patient group were significantly greater in both zorbtive ® -treated groups than in the control group. table 3: randomized, placebo controlled trial of zorbtive ® in adult patients with short bowel syndrome: results for endpoints after 4 weeks of treatment zorbtive ® alone zorbtive ® + glutamine control (placebo + glutamine) total ipn volume (l/wk) mean at baseline 10.3 10.5 13.5 mean change -5.9 -7.7 -3.8 treatment differences (with control) -2.1* -3.9** total ipn calories (kcal/wk) mean at baseline 7634.7 7895.0 8570.4 mean change -4338.3 -5751.2 -2633.3 treatment differences (with control) -1705.0 -3117.9 frequency of ipn or sle (days/wk) mean at baseline 5.1 5.4 5.9 mean change -3.0 -4.2 -2.0 treatment differences (with control) -1.0 -2.2

d. instruct patients to rotate injection sites to avoid localized tissue atrophy [see warnings and precautions (5.5) ] . refer patients to the instructions for use on how to prepare and administer an injection of zorbtive. fluid retention/carpel tunnel syndrome inform patients that increased tissue turgor (swelling, particularly in the hands and feet) and musculoskeletal discomfort (pain, swelling and/or stiffness) may occur during treatment with zorbtive ® and to report to their healthcare provider any signs or symptoms that occur during treatment with zorbtive ® [see warnings and precautions (5.6 and 5.7) ]. pancreatitis inform patients that pancreatitis may develop and to report to their healthcare provider any new onset abdominal pain [see warnings and precautions (5.8) ]. hypoadrenalism inform patients who have or who are at risk for pituitary hormone deficiency(s) that hypoadrenalism may develop and to report to their healthcare provider if they experience hyperpigmentation, extreme fatigue, dizziness, weakness, or weight loss [see warnings and precautions (5.9) ]. hypothyroidism inform patients that hypothyroidism may develop and that their thyroid function may be monitored before starting zorbtive ® and again following 4 weeks of treatment [see warnings and precautions (5.10) ] . intracranial hypertension instruct patients to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting [see warnings and precautions (5.11) ].

see the end of this leaflet for a complete list of ingredients in zorbtive ® . talk to your healthcare provider before using this medicine if you have any of these conditions. before using zorbtive ® , tell your healthcare provider about all of your medical conditions, including if you: had cancer have diabetes or blood sugar problems have or had numbness and tingling in your wrist and hand (carpal tunnel syndrome) have thyroid problems (hypothyroidism) have pancreas problems have kidney or liver problems are pregnant or plan to become pregnant. it is not known if zorbtive ® will harm your unborn baby. are breastfeeding or plan to breastfeed. it is not known if zorbtive ® passes into your breast milk. talk to your healthcare provider about the best way to feed your baby while using zorbtive ® . tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. zorbtive ® and other medicines may affect each other causing serious side effects. ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. know the medicines you take. keep a list of them to show your healthcare provider when you get a new medicine. how should i use zorbtive ® ? see the instructions for use at the end of this leaflet for detailed instructions about how to inject zorbtive ® the right way. do not use zorbtive ® until your healthcare provider has shown you how to inject zorbtive ® the right way. use zorbtive ® exactly as your healthcare provider tells you to. your healthcare provider will tell you how much zorbtive ® to use and when to use it. your healthcare provider may change your dose if needed. zorbtive ® is injected under the skin (subcutaneously) 1 time a day for 4 weeks. your healthcare provider will tell you where to inject zorbtive ® . some examples of common injection sites include the top side of the thigh, the areas around the belly button, the back of the upper arms, and the buttocks or hips. change (rotate) your injection site with each injection. do not inject zorbtive ® into skin that is tender, bruised, red, or hard. always use a new, unopened, needle and syringe for each injection. never reuse needles and syringes. throw away used needles and syringes in a fda approved sharps container. see " disposing of used needles and syringes " in the zorbtive ® instructions for use. what are the possible side effects of zorbtive ® ? zorbtive ® may cause serious side effects, including: return of tumor or cancerous growth. if you had cancer in the past, using zorbtive ® may cause your cancer to come back. see " who should not use zorbtive ® " above. diabetes or blood sugar problems. zorbtive ® can cause diabetes or blood sugar problems that do not go away after you stop using zorbtive ® . zorbtive ® can also cause your diabetes and blood sugar problems that you already have to get worse. your healthcare provider may need to check your blood sugar or change your diabetes medicines while you are using zorbtive ® . serious allergic reactions. stop using zorbtive ® and go to the nearest hospital emergency room right away if you have any signs or symptoms indicating anaphylactic shock which may include fainting, confusion, trouble swallowing, and difficulty breathing. injection site reactions (atrophy). zorbtive ® may cause redness, itching, and tissue weakness in the area of skin you injected. changing (rotating) your injection site each time may lower the chances of injection site atrophy. swelling of your hands and feet (fluid retention). call your healthcare provider if you have any swelling of your hands and feet. numbness and tingling in your wrist and hand (carpal tunnel syndrome). decrease in thyroid hormone levels in your blood (hypothyroidism). your healthcare provider will do blood tests to check your thyroid function before you start and 4 weeks after you stop using zorbtive ® . decreased function of adrenal glands (hypoadrenalism). call your healthcare provider if you experience changes in skin color, extreme tiredness, dizziness, weakness, or unexplained weight loss. pancreatitis. call your healthcare provider or go to the nearest hospital emergency room right away if you have any signs or symptoms of sudden pancreatitis including: severe pain in the upper stomach area sweating, nausea, vomiting skin and whites of the eyes turn yellow swollen and tender stomach area fever fast heart beat increased pressure in your skull (intracranial hypertension). your healthcare provider may test your eyes while you use zorbtive ® . call your healthcare provider or go to the nearest hospital emergency room right away if you have any signs or symptoms of intracranial hypertension including: headaches nausea or vomiting vision changes benzyl alcohol toxicity . benzyl alcohol is a preservative in the bacteriostatic water for injection (water for mixing the multi-dose vial of zorbtive ® ). benzyl alcohol has caused serious side effects, including death, in children, especially premature and low-birth weight infants who received the preservative benzyl alcohol. ask your healthcare provider or pharmacist for plain sterile water for mixing with zorbtive ® if you are allergic to benzyl alcohol. the most common side effects of zorbtive ® include: swelling of the arms, legs, hands, feet, face gas nausea stomach area (abdominal), injection site pain muscle pain and stiffness injection site reactions vomiting pain these are not all the possible side effects of zorbtive ® . call your doctor for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. how should i store zorbtive ® ? store unmixed vials of zorbtive ® , sterile water, and bacteriostatic water for injection, usp (0.9% benzyl alcohol), at room temperature between 59°f to 86°f (15°c to 30°c). store zorbtive ® mixed with bacteriostatic water for injection, usp (0.9% benzyl alcohol) in the refrigerator between 36°f to 46°f (2°c to 8°c) for up to 14 days (2 weeks). zorbtive ® mixed with sterile water should be used right away. throw away any unused zorbtive ® mixed with sterile water. do not store it for later use. do not freeze mixed zorbtive ® . do not use zorbtive ® past the expiration date printed on the carton. throw away medicine that is past the expiration date or no longer needed. keep zorbtive ® and all medicines out of the reach of children. general information about the safe and effective use of zorbtive ® . medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. do not use zorbtive ® for a condition for which it was not prescribed. do not give zorbtive ® to other people, even if they have the same symptoms that you have. it may harm them. you can ask your pharmacist or healthcare provider for information about zorbtive ® that is written for health professionals. what are the ingredients in zorbtive ® ? active ingredient: somatropin inactive ingredients: sucrose, phosphoric acid